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Abstract
Background: Endoscopic ultrasonography with fine needle aspiration (EUS-FNA) has become an inte-
gral tool in the diagnosis of pancreatic cystic lesions (PCLs) and the analysis of molecular/DNA abnor-
malities might improve the accuracy of pre-operative diagnosis. A review was conducted of all studies
using EUS-FNA aspirates of PCLs to assess the accuracy and added benefit that molecular analysis
provides to cytological analysis.
Methods: A systematic review of the literature was conducted using PRISMA guidelines and electronic
databases: PubMed/SCOPUS/EMBASE/Cochrane/CINAHL. Surgical pathology was used as the defini-
tive reference standard. The QUADAS-2 tool was used for quality assessment.
Results: In total, 162 articles were identified; 12 articles met inclusion/exclusion criteria. Ten studies
reported on cytology and 8 studies reported k-ras mutational analysis. 362 patients (of 1115 total) had
surgical pathology available. The sensitivity and specificity of cytology was 0.42 and 0.99; the sensitivity
and specificity of k-ras was 0.39 and 0.95; and the sensitivity and specificity of the combined test of
cytology and k-ras was 0.71 and 0.88, respectively.
Conclusions: k-ras mutational analysis used as an individual screening test has a poor diagnostic
accuracy, as does cytology when used alone. The benefit comes with utilization in a combined fashion.
More studies are needed to evaluate the correct sequence and utility of these tests for cyst differentiation.
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Introduction
Pancreatic cystic lesions (PCLs) present an emerging diagnostic
dilemma. The prevalence is estimated at approximately 1% of the
general population,1 yet the frequency of diagnosis has been
increasing in recent years,2 as a result of incidental findings with
the widespread use of diagnostic imaging. Pseudocysts, serous cyst
adenomas and solid pseudopapillary tumours are, for the most
part, considered benign, whereas mucinous cystic neoplasms
[comprised of intraductal papillary mucinous neoplasms
(IPMNs) and mucinous cystic neoplasms (MCNs)] are consid-
ered pre-malignant entities, which are at risk of degeneration and
may harbour malignant change.
The overall diagnostic accuracy for CT scans in the setting of
PCLs varies in the literature between 20% and 83%.3–5 Endoscopic
ultrasonography (EUS) has become an integral tool in the differ-
entiation and diagnosis of PCLs. Fine needle aspiration of cyst
fluid using this modality (EUS-FNA) has provided a means of
further characterizing a lesion in an effort to determine best
management.
EUS-FNA-based cytology has shown in a meta-analysis6 a sen-
sitivity and specificity of 0.63 and 0.88, respectively. CEA meas-
urement, with an optimal cut-off of 192 ng/ml, has been
advocated by the Cooperative Pancreatic Cyst Study Group as the
test with the greatest accuracy for differentiating mucinous versus
non-mucinous cystic lesions, with a sensitivity of 0.75 and a speci-
ficity of 0.84.7
Recent advances have allowed testing of the fluid for molecular/
DNA abnormalities to improve insight and possibly accuracy of
pre-operative diagnosis. Molecular analysis currently includes the
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assessment for k-ras mutations, DNA quantification and loss of
heterozygosis (LOH) of a pre-determined array of alleles (com-
mercially available, Pathfinder TGR; RedPath integrated Pathol-
ogy, Inc., Pittsburgh, PA, USA). Sensitivities for cytological
analysis have varied in the literature. The addition of molecular
testing has had variable sensitivities and specificities, ranging from
16% to 86% and 93% to 100%8,9, respectively.When only the k-ras
mutation is considered, sensitivity ranges from 11% to 64.7%10,11
whereas specificity ranges from 76% to 100%.9,12 Previously pub-
lished review articles6,13,14 have stressed that the use of molecular
analysis has a role in differentiating pancreatic cystic lesions, but
the actual added benefit of molecular testing to cytology to
improve the diagnostic accuracy of pre-operative FNA analysis is
unknown.
The aim of this study was to conduct a systematic review of all
studies using molecular evaluation of EUS-FNA aspirates of cystic
pancreatic lesions, and to assess the accuracy and added benefit
that molecular analysis provides to cytological analysis, when
compared with the definitive pathologic diagnosis.
Methods
A systematic review of the literature was conducted using
PRISMA guidelines designed for systematic review and
meta-analysis.15
Search strategy
A comprehensive search was made of the following electronic
databases: PubMed, SCOPUS, EMBASE, Cochrane and CINAHL.
A combination of MeSH and text words was used.
The search terms used were: ‘pancreatic/pancreas neoplasm(s)/
lesion(s)/tumour(s)/tumor(s)’, ‘cystic/cyst(s)’, ‘endosonography/
endoscopic ultrasound/endoscopic echography/endoscopic
ultrasonography/EUS’, ‘fine needle aspiration/FNA’ and ‘molecu-
lar analysis/molecular biology/DNA/k(-)ras/k(-)ras mutation’.
The search was restricted to humans. No language restriction was
applied. The references of the selected studies and relevant jour-
nals were hand-searched for further articles.
Inclusion criteria
All diagnostic, cross-sectional studies and cohort studies of test
accuracy comparing molecular analysis of cystic fluid obtained
through EUS-FNA of pancreatic cystic lesions were included.
Studies also had to provide sufficient data to allow for the con-
struction of a 2 × 2 table.
Exclusion criteria
All case reports, letters to the editor and reviews were excluded.
Studies involving solid lesions were excluded as were any studies
in which molecular analysis was not used, or those that used other
methods of FNA sampling, such as radiologically guided modali-
ties. Studies in which a surgical pathological specimen was not
available as reference were also excluded.
Participants
Study participants included all patients with pancreatic cystic
lesions, incidentally found or purposely investigated, presenting
with or without symptoms, and that had definitive pathological
analysis of the cystic lesion.
Tests under investigation
The index test was molecular analysis. This includes the assess-
ment of the k-ras mutation, specific allelic imbalances (LOH), and
DNA quality and quantity. A commercial panel of DNA allelic
analysis is available (Pathfinder).
The comparator test was cytology. A positive cytological diag-
nosis included all samples read as atypical, suspicious, positive or
malignant. Negative cytology included all results read as indeter-
minate, acellular or negative. Surgical pathology was the reference
standard. It should be noted that a diagnosis of atypia within a
cytological sample does not definitively indicate malignancy man-
dating resection. For the purposes of analysis within this study, the
presence of any abnormality of cytology was considered positive.
Abnormalities within cytology would flag the specimen as con-
cerning and worthy of further evaluation.
Data abstraction
Two authors (I.C. and A.G.) independently conducted the litera-
ture search and reviewed search results, first by title and abstract,
and where necessary by review of full text of the study report, to
determine inclusion or exclusion. A third author (K.C.) was avail-
able for arbitration, and to establish consensus in the event of
disagreement.
A standardized data extraction form was used to abstract study
design features and results data from each publication. For each
study, data (including: year of publication, country of study, study
design, clinical setting, number of male and female for each study
and incidence of malignancy based on surgical pathology) were
extracted independently by two authors.
2 × 2 tables were constructed for each included study, for the
variables of cytology, molecular analysis, K-ras and LOH where
available. These data were then collected in a spread sheet. When
necessary, authors were contacted to provide further information.
Quality assessment
Methodological quality of included primary studies was assessed
by two authors (I.C. and A.G.) using the modified QUADAS-2
tool.16
Statistical analysis
The bivariate random effect model was used to calculate summary
estimates of sensitivity and specificity and the corresponding con-
fidence intervals. This approach was preferred, as it preserves the
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two-dimensional nature of the original data and takes into
account both study size and heterogeneity present beyond chance
between studies.17
Heterogeneity was visually evaluated using the summary ROC
plots and statistically, using the variance of logit transformed sen-
sitivity and specificity, with smaller values indicating less hetero-
geneity among studies.
Using the Bayes theorem, the post-test odds of mucinous lesion
were estimated by multiplying the pre-test odds by the likelihood
ratio, where the pre-test odds is calculated by dividing the pre-test
probability by (1 – pre-test probability) and the post-test prob-
ability is calculated as post-test odds divided by (1 + post-test
odds).
Stata version 12 (StataCorp College Station, Texas, USA), par-
ticularly the metandi command, was used for all statistical analy-
ses. 2 × 2 tables were constructed for each included study, for the
variables of cytology, molecular analysis, K-ras and LOH where
available. A subgroup analysis to investigate the specific value of
K-ras and LOH was performed when possible.
Results
Systematic review
Our initial search revealed 162 study titles and abstracts. Figure 1
describes the selection process of articles. Of these, 12 studies met
the inclusion and exclusion criteria. Ten studies were from the
United States,9,12,18–25 one study was from Poland,11 and one from
Australia.26 Eight studies were retrospective9,11,12,20–22,24,26 and four
studies were prospective.18,19,23,25 The studies included a total of
1115 patients, of which 362 had surgical pathology available for
comparison, and thus were included for evaluation. The charac-
teristics of the included studies are presented in Table 1; the
pathologic diagnosis, cytological and molecular findings available
for the patients who met inclusion criteria are recorded in Table 2.
Quality assessment
The included studies were evaluated using the QUADAS-2 tool,
assessing for both bias and applicability. The QUADAS-2 tool
assesses articles for systematic reviews of diagnostic accuracy
studies. It assesses quality in four domains: patient selection, the
index test, the reference standard, and flow and timing. The
studies included in this review all showed an evaluation of ‘low
concern’, as the index test (molecular analysis) and the reference
standard (surgical pathology) are reliable and consistently admin-
istered within each article. However, a high risk of bias was dem-
onstrated within domain four, addressing the issue of whether all
patients within the study were included in the evaluation. A large
number of patients were excluded within each study as the inclu-
sion criterion requiring surgical pathology as the reference stand-
ard could not be met. As a result of this bias, specificity, although
calculated, cannot be reliably interpreted. The cytology and
molecular data for any patients lacking definitive histology could
not be included, potentially overestimating the overall sensitivity
of both diagnostic measures.
Meta-analysis
Ten articles were included in the meta-analysis for diagnostic
accuracy of cytology (two articles did not report cytology).22,25
From these, six articles9,11,18,21,23,26 presented cytology differentials as
malignant,mucinous, intermediate, benign, negative, or not avail-
able, and did not use a classification of atypia. Four articles12,19,20,24
used a classification of atypia for cytology. Owing to the nature of
the search criteria, all patients with an atypical diagnosis (50
patients in total) went on to have definitive histology available, save
for 6 patients, who were recommended for definitive resection, but
did not go on to have surgery due to refusal or poor candidacy for
surgery. No further follow-up was available for these six patients.12
All articles provided information on molecular analysis, which
could include k-ras mutation analysis, ≥2 allelic LOH using the
commercially available panel (Pathfinder TGR) or DNA quantifi-
cation. Only three studies22–24 reported sufficient results for LOH
to create a 2 × 2 table. DNA quantification was not reported
extensively enough to allow for evaluation. Subset analysis of eight
articles11,12,19,22–26 providing information specifically for k-ras
mutations was performed.
Figures 2 and 3 show the Forest plots of sensitivity and speci-
ficity for cytology and k-ras mutation analysis, respectively, in the
assessment of pancreatic mucinous cystic lesions. The Forest plots
for cytology show variable sensitivities within the papers from
0.10–1.0, with 6 of the 10 papers9,12,19–21,23 recording sensitivity of
cytology as scoring greater than 0.5. The sensitivity for the k-ras
mutation show less variable results among the studies, varying
from 0.12–0.75, with only 2 of the 8 articles11,26 scoring greater
than 0.5.
This relationship is further displayed in Figs 4 and 5 by calcu-
lating the summary receiver-operating curves (SROC) for the sen-
sitivity and specificity for cytology and k-ras mutational analysis.
Figure 4 displays the SROC of cytology analysis for the 10 articles,
showing the sensitivity of the individual articles mapped on the
vertical scale, specificity on the horizontal scale, with the summary
sensitivity point marked. The results of the studies have notable
variation as shown by the wide confidence region. The sensitivity
of this group is 0.41 [95% confidence interval (CI), 0.24–0.60]
with a specificity of 0.99 (95% CI, 0.27–0.99). Similarly, Fig. 5
displays the SROC for the k-ras mutation within the eight articles
that provided details in this regard. The sensitivity and specificity
for k-ras mutation analysis is 0.39 (95% CI, 0.28–0.51) and 0.95
(95%CI, 0.83–0.99), respectively. The studies included here have a
narrower confidence interval. To analyse the combined effect of
the two individual tests, the SROC of both cytology and k-ras was
analysed using the five articles in which it was available (Fig. 6).
The sensitivity of the combined test is 0.71 (95% CI, 0.41–0.93)
with a specificity of 0.88 (95% CI, 0.42–0.98).
Discussion
Pancreatic cystic lesions present a diagnostic challenge. Reliably
identifying the nature of the lesion pre-operatively is needed to
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162 Titles/Abstracts identified from
initial search
119 Abstracts reviewed
29 full articles reviewed
7 Eligible
43 exluded by title − topic
not EUS-FNA, cytology,
pancreatic cyst
90 excluded: review articles,
topic not including pancreatic
cysts, no molecular analysis
22 excluded: 21-abstracts
only, no published articles
available
1 - patient group used in the
article was already included in
the study through a previously
selected article
5 articles identified through
search of references of
selected articles
12 studies included for analysis
Figure 1 Flow diagram of study selection for systematic review (PRISMA)
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Table 1 Demographics of included studies
Study Study design N
Total
Gender Age
(years)
Location of
cystic lesions
Cyst size Incidence of
malignancy
N
Male
N
Female
Khalid (2005)18
USA
Prospective 36 15 21 Mean(Malig.): 69
Mean(Pre-Malig.): 63
Mean(Benign): 43
NR Mean
(Malignant):
3.9 cm
Mean
(Pre-Malignant):
2.8 cm
Mean (Benign):
4.8 cm
67.74%
Schoedel (2006)24
USA
Retrospective 16 NR NR NR NR NR 25%
Khalid (2009)19
USA
Prospective 113 45 68 Mean: 63.1
Median: 65
Head/Uncinate:
47%
Body: 33%
Tail: 21 %
Diffuse: 1.8%
0–2 cm: 40.7%
2–4 cm: 38.9%
>4 cm: 20.4%
71.26%
Sawhney (2009)20
USA
Retrospective 100 35 65 Mean: 63 ± 14 Head/Uncinate:
43%
Body: 39%
Tail: 18 %
Mean: 2.5 cm ±
2.2 cm
(Range:
0.8–14 cm)
89.47%
Shen (2009)9
USA
Retrospective 35 8 27 Mean: 65
(Range: 31–85)
Head/Uncinate:
51.4%
Body: 37.1%
Tail: 11.4 %
Mean
(Malignant):3.1 cm
Mean (Benign
Mucinous):2.2 cm
Mean (Benign
Non-Mucinous):
3.7 cm
75%
Sreenarasimhaiah (2009)22
USA
Retrospective 20 NR NR Mean (Male): 62.8
Mean (Female): 61.3
NR NR 100%
Mertz (2011)12
USA
Retrospective 60 NR NR Mean: 66
(No Range)
Head/Uncinate:
50%
Body: 20%
Tail: 8.3 %
Unknown: 21.7%
Mean (all cysts):
1.9 cm
Mean (No
Atypia):
2.0 cm
Mean (Atypia):
1.9 cm
70%
Toll (2010)21
USA
Retrospective 63 38 25 Mean: 69
(Range:18–91)
Head/Uncinate:
36.5%
Body: 31.7%
Tail: 11.1 %
Diffuse: 36.5%
All cysts ≤ 3 cm 50%
Panarelli (2012)23a
USA
Prospective 18 3 15 Mean: 65
(Range: 35–79)
‘..evenly distributed
in pancreatic
body, head, and
tail.. 1 lesion in
the uncinate
process.’
Mean: 2.5 cm
Median: 1.9 cm
(Range:0.5–5 cm)
100%
Talar-Wojnarowska (2012)11
Poland
Retrospective 56 31 25 Mean: 57 ± 3.4 Head/Uncinate:
53.6%
Body/Tail: 46.4%
Mean (Malig./
Pre-Malig.):
3.2 cm ±
2.2 cm
Mean (Benign):
3.7 cm ±
2.7 cm
51%
Chai (2013)26b
Australia
Retrospective 52 25 27 Mean: 62
(Range: 8–85)
Head/Uncinate:
40.7%
Body: 20.4% Tail:
38.9%
NR 50%
Nikiforova (2013)25c
USA
Prospective 546 32% 68% Mean: 63.9
(Range: 17–90)
Head/Uncinate:
40%
Body: 38% Tail:
22%
Mean:2.3 cm
(Range:
(0.6–11 cm)
8%
a20 cysts in 18 patients.
b54 cysts in 52 patients.
c618 cysts in 546 patients.
NR, not recorded.
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Sensitivity (95% Cl) Specificity  (95% Cl)
0.75 [0.19-0.99]Panarelli 2012
Schoedel 2006
Chai 2013
Talar 2013
Khalid 2009
Mertz 2011
Toll 2010
Sawhney 2009
Shen 2009
Khalid 2005
Panarelli 2012
Schoedel 2006
Chai 2013
Talar 2013
Khalid 2009
Mertz 2011
Toll 2010
Sawhney 2009
Shen 2009
Khalid 2005
0.13 [0.02-0.40]
0.50 [0.07-0.93]
0.18 [0.04-0.43]
0.62 [0.49-0.74]
0.57 [0.18-0.90]
1.00 [0.03-1.00]
0.59 [0.33-0.82]
0.60 [0.15-0.95]
0.10 [0.01-0.30]
0.0 SENSITIVITY 1.0
Chi Squared = 35.67; 
df = 9 (p = 0.00)
I-squared (inconsistency) = 
74.77 [59.01-90.52]
Chi Squared = 31.19; 
df = 7 (p = 0.00)
I-squared (inconsistency) 
= 77.56 [62.24-92.87]
1.00 [0.40-1.00]
N/A
N/A
1.00 [0.79-1.00]
1.00 [0.86-1.00]
0.67 [0.09-0.99]
1.00 [0.03-1.00]
1.00 [0.16-1.00]
1.00 [0.16-1.00]
1.00 [0.69-1.00]
0.0 1.0SPECIFICITY
Figure 2 Forest plot of sensitivity and specificity for cytology. The horizontal lines represent the 95% confidence interval (CI) for each study.
The vertical bar (broken) represents the estimated pooled sensitivity/specificity
Table 2 Pathological, molecular and cytological values
Study N
Total
N
Cytology
N
k-ras
N
LOH
N
Molecular
N
Histology
NI/E Diagnosis
Malignant
(Adeno/
CIS/NET)
IPMN/ MCN Benign
(PC/RC/
SCA/LC/CP)
Khalid (2005) 36 36 – – 36 31 31 6 15 10
Schoedel (2006) 16 15 16 15 15 16 16 4 12 –
Khalid (2009) 113 112 113 – – 87 83a 10 48 25
Sawhney (2009) 100 100 – – 100 19 19 5 12 2
Shen (2009) 35 29 – – 35 8 8 3 3 2
Sreenarasimhaiah (2009) 20 20 20 20 – 6 6 2 4 –
Mertz (2011) 60 60 60 – – 10 10 – 7 3
Toll (2010) 63 63 – – 63 2 2 1 – 1
Panarelli (2012)b 18 18 18 18 – 4 4 1 3 –
Talar-Wojnarowska (2012) 56 56 56 – – 33 33 4 13 16
Chai (2013)c 52 52 50 – – 8 8 – 4 4
Nikiforova (2013)d 546 – 603 (cysts) – – 142 142 31 85 26
a4 patients were excluded as the molecular analysis could not be confirmed;
b20 cysts in 18 patients;
c54 cysts in 52 patients;
d618 cysts in 546 patients; NI/E number of patients meeting inclusion criteria.
IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm; CIS, carcinoma insitu; PC, pseudocyst; RC, retention cysts; SCA,
serous cyst adenoma; LC, lymphoepithelial cyst; DC, duplication cyst; CP, chronic pancreatitis; NET, neuroendocrine tumour.
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avoid unnecessary resection. Traditional imaging with computed
tomography and magnetic resonance imaging has a variable accu-
racy from 20–80%.13 The advent of EUS as a diagnostic modality
has also shown variable accuracy in correctly identifying
mucinous cystic lesions (40–93%)13 but more importantly has
provided an avenue of fluid procurement for analysis that was
previously unavailable.
To assist in diagnosis, tumour marker analysis (CEA), cytology
and mutational analysis of the cystic fluid (specifically for k-ras)
have been used in an effort to more accurately identify lesions in
the pre-operative phase. The majority of FNA-based investiga-
tions [e.g. cytology, CEA, amylase and mutational analysis (spe-
cifically k-ras)] have high specificity, but low sensitivity.
Mutational analysis, particularly, has become of interest, although
commercially available assays are costly and may not be as accu-
rate in identifying smaller uncomplicated cysts, lacking in clinical
or radiological features of concern (pain, loculation and mural
nodules).23 In this meta-analysis we attempted to examine the
added benefit that molecular testing, and specifically k-ras testing,
applies in the differentiation of mucinous and non-mucinous
cysts.
Analysis of aspirate fluid for cytology has been analysed in two
meta-analyses, in 200527 and again in 2010.6 Van der Waaij et al.
included 12 articles, and in pooled analysis found a sensitivity for
cytology of 35%, with a specificity of 83%. Thosani included 11
studies and presented a cytological sensitivity of 63% with a high
specificity of 88% in differentiating mucinous from non-
mucinous lesions. These two meta-analysis have three shared arti-
cles only. The sensitivity of cytology from this current meta-
analysis is poor, < 50%, indicating a test of poor diagnostic
accuracy. Only one article has been shared19 with the most recent
cytological meta-analysis. Thosani et al. specify the reported
pooled sensitivity may be an overestimation owing to verification
bias. Verification bias can also be considered a concern with this
meta-analysis. Due to the inclusion criterion of surgical/
histological confirmation necessary as a reference standard, a
number of patients were excluded, as this criterion was not ful-
filled. This could account for the discrepancy in values between
Sensitivity (95% Cl) Specificity (95% Cl)
0.33 [0.04-0.78]
Panarelli 2012
Schoedel 2006
Chai 2013
Talar 2013
Khalid 2009
Mertz 2011
Nikiforova 2013
Sawhney 2009
Sreenarasimhalah 2009
Panarelli 2012
Schoedel 2006
Chai 2013
Talar 2013
Khalid 2009
Mertz 2011
Nikiforova 2013
Sawhney 2009
Sreenarasimhalah 2009
0.25 [0.07-0.52]
0.25 [0.01-0.81]
0.43 [0.10-0.82]
0.65 [0.38-0.86]
0.12 [0.01-0.36]
0.75 [0.19-0.99]
0.41 [0.29-0.55]
0.46 [0.36-0.55]
0.0
SENSITIVITY
1.0
Chi Squared = 15.98;
df = 8 (p = 0.04)
I-squared (inconsistency) 
= 49.95 [11.52-88.07]
Chi Squared = 8.00; 
df = 5 (p = 0.16)
I-squared (inconsistency) 
= 37.46 [0.00-95.07]
1.00 [0.40-1.00]
N/A
N/A
N/A
0.94 [0.70-1.00]
0.67 [0.09-0.99]
1.00 [0.16-1.00]
1.96 [0.80-1.00]
1.00 [0.37-1.00]
0.1
SPECIFICITY 1.0
Figure 3 Forest plot of sensitivity and specificity for k-ras. The horizontal lines represent the 95% confidence interval (CI) for each study. The
vertical bar (broken) represents the estimated pooled sensitivity/specificity
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this meta-analysis and those performed previously. Regardless, the
overall sensitivity of cytology as an independent test is poor.
In an effort to improve diagnostic accuracy of testing, analysis
for common pancreatic cell mutations within mucinous fluid
characteristic of mucinous/pre-malignant or malignant lesions
has been investigated. DNA mutational analysis of mucinous
cystic lesions, specifically for k-ras, has been shown to have
varying accuracy, with a sensitivity and specificity of
11–64.7%9,11,19,20,22 and 92–100%11,19,20,22, respectively. In a recent
review,14 the sensitivity of k-ras was quoted to be ∼50% with a
specificity 98%. The low sensitivity of k-ras for discerning
mucinous versus non-mucinous lesions makes it of little use as an
independent screening test. Owing to its high specificity, a nega-
tive diagnosis is reasonably reassuring, indicative of a non-
mutation, less likely mucinous, however, as a negative value it has
little clinical impact with a relatively high price tag. From the data
supplied here, there is insufficient evidence, at present, to assign a
role for LOH in routine FNA cyst fluid analysis.
When analysed concurrently, cytology and the presence of the
k-ras mutation, the sensitivity was 0.71 showing a 30% improve-
ment in diagnosis adding k-ras analysis to a cytology diagnosis,
sensitivity of 0.41. The use of mutation analysis in this investiga-
tional setting is adjunctive, rather than replacement. As noted by
Khalid et al.,19 combinations of multiple tests work synergistically
to improve diagnostic accuracy, framed within a cost-aware envi-
ronment. Beginning with established cytological methods, k-ras
mutation analysis and CEA seem to be the most reliable means of
identifying lesions. Talar-Wojnarowska et al.11 examined K-ras
combined with CEA analysis (CEA level cut off >45 ng/ml) cor-
rectly identified 94.1% of all lesions. Sawhney et al.20 found
minimal agreement with the CEA level and molecular analysis, in
identifying mucinous lesions, although when combined together,
accuracy was greatly improved to 100% on those confirmed with
a pathological specimen.As put forward in the model presented in
a recent review, the use of cytology, CEA and k-ras mutational
analysis in a complementary fashion would be the recom-
mended,14 and LOH and further DNA quantification cannot be
recommended for routine investigational purposes at this time.
Each of these studies was evaluated with the QUADAS-2 tool,
which examines risk of bias. The stringent inclusion criteria
demanded the use of surgical pathology as the reference standard
which limited bias from interpretation. The studies, for the most
part, reported information transparently, suitable for reproduc-
tion analysis, and where needed, authors were contacted for infor-
mation verification. If information could not be verified, it was
not included in analysis.
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Figure 4 Summary receiver-operating characteristic (SROC) curve
for cytology (10 studies)
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Figure 5 Summary receiver-operating characteristic (SROC) curve
for k-ras (8 studies)
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This study is exposed to certain limitations. Due to inclusion
criteria, only a subset of patients could be included for analysis, as
only that portion underwent surgical resection, resulting in a
partial verification bias. This occurred as all patients within the
separate studies received the diagnostic test, only a subgroup of
patients underwent the reference standard (surgical resection)
and thus only these patients could be included for analysis. This
interferes with the ability to accurately calculate specificity of the
diagnostic tests. A second limitation is the low number of studies.
The literature search identified a number of abstracts related to
the topic, and would have passed inclusion criteria on screening,
however, these were in abstract form only, and the original article
had not been published at the time of literature analysis. This
represents a publication bias.
Conclusions
This study has demonstrated that k-ras mutational analysis used
as an individual screening test is of poor diagnostic accuracy, as is
cytology when used alone. The benefit of these tests comes with
utilization in a combined fashion, including CEA analysis. Previ-
ous review articles have also alluded to these issues; this article has
quantified the differences and has provided support for the use of
molecular analysis but its precise role is uncertain. Although the
combination of these tests has been demonstrated here to improve
accuracy to an acceptable level for diagnostic use, there is still
much room for error, particularly on small cysts. New mutational
markers are being explored in an effort to further differentiate
cystic lesions. More studies are needed to evaluate the correct
sequence and utility of tests to differentiate between benign and
malignant cysts. Routine use of molecular analysis cannot be
advocated based on these results, and should be reserved for cases
with sufficient clinical suspicion.
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